Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2016 Feb 11;25(5):736–744. doi: 10.1158/1055-9965.EPI-15-1111

Figure 1.

Figure 1

Seroprevalences of human polyomaviruses (PyV) as determined by VP1 seroreactivity among 229 controls by age group from the Skin Cancer Prevention Study, using the baseline or earliest serum sample collected. The overall seroprevalence (%) and number of participants who were seropositive for each PyV is shown above the bars. The number of participants within each age group is noted in the legend.